BrainStorm (OTC.OB:BCLI) is developing innovative adult stem cell therapies for highly debilitating neurodegenerative disorders such as ALS (Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD). Their proprietary process for the propagation and differentiation of autologous, Mesenchymal Stem Cells (MSC) into NeuroTrophic Factor (NTF)-secreting cells, and their transplantation at or near the site of damage, offers the hope of repairing degenerated tissues and curing the underlying pathology, rather than simply treating its symptoms